Patricia G. Hoogeveen

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

Vincent H. J. van der Velden, Jeroen G. te Marvelde, Patricia G. Hoogeveen et al. · Blood · 2001 · 338 citations

Medicine, Oncology, Pharmacology +17

Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

Vincent H. J. van der Velden, A van der Sluijs-Geling, B Gibson et al. · Leukemia · 2010 · 145 citations

Medicine, Hematology, Oncology +17

High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients

Vincent H. J. van der Velden, Nancy Boeckx, Inge Jedema et al. · Leukemia · 2004 · 115 citations · Full text

Medicine, Hematology, Oncology +13

Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients

Floor Weerkamp, E Dekking, Yuk Yin Ng et al. · Leukemia · 2009 · 74 citations

Medicine, Hematology, Oncology +12

Vδ2-Jα rearrangements are frequent in precursor-B–acute lymphoblastic leukemia but rare in normal lymphoid cells

Tomasz Szczepański, Vincent H. J. van der Velden, Patricia G. Hoogeveen et al. · Blood · 2003 · 73 citations · Full text

Medicine, Hematology, Oncology +13